Evidence Table 11Efficacy of Other Treatments1,2

StudyTreatment# of patients improved/N (%)Odds ratioMean ValuesEffect size or p-value
NBefore TreatmentAfter Treatment
HORMONAL TREATMENTS
Estradiol vs. placebo
Dennerstein, Morse, Burrows, et al., 1988Estradiol (percutaneous gel), 1.5 mg/day, 7 days, for 2 menstrual cycles--19*--0.71 (0.26 to 1.2)
HF(within-patients difference)
Placebo-19*--
Smits, van der Meer, Pfeil, et al., 1993Estradiol (Estraderm TTS® patch), 50 μg/day for 8 days during 1–2 menstrual cycles (see Evidence Table 1)--19*--n.s. (no p-value reported)
HF
Placebo-19*--
Flumedroxone vs. placebo
Bradley, Hudgson, Foster, et al., 1968
(Men)
Flumedroxone, 30 mg/day for 3 mos--14*--n.s. (no p-value reported)
HI (within-patients difference)
Placebo-14*--
Bradley, Hudgson, Foster, et al., 1968
(Women w/o menstrual exacerbation of HA)
Flumedroxone, 30 mg/day for 3 mos--7*--n.s. (no p-value reported)
HI (within-patients difference)
Placebo-7*--
Bradley, Hudgson, Foster, et al., 1968
(Women with menstrual exacerbation of HA)
Flumedroxone, mos 30 mg/day for 3--18*--p<0.05 (flumedroxone better)
HI (within-patients difference)
Placebo-18*--
Lundberg, 1969Flumedroxone, 10 mg/day for 1 mo--21--p<0.0005 (flumedroxone better)
HF
Placebo-23--
Flumedroxone vs. methysergide
Hudgson, Foster, and Newell, 1967Flumedroxone, 15 mg/day for 4 mos--33*-4.3-
HF
Methysergide, 3 mg/day for 4 mos-33*-2.8
Ovral® (norgestrel 0.5 mg + ethinyl estradiol 0.005 mg) vs. no treatment
Ryan, 1978Ovral®, as prescribed, for 2 mos--40*-48.70-
HI
No treatment-40*-32.85
FEVERFEW
Johnson, Kadam, Hylands, et al., 198550 mg/day for 6 mos--8-1.502.3 (1.0 to 3.6)
HF
Placebo-7-3.43
Murphy, Heptinstall, and Mitchell, 1988Feverfew, ≈82 mg/day (mean dose) for 4 mos--59*-3.60.56 (0.19 to 0.93)
HF
Placebo-59*-4.7
1

Key to abbreviations: ES = effect size; Freq = frequency; HA = headache; HF = headache frequency; HI = headache index; HS = headache severity; Imprv'd = improved; MD = medical doctor; med = medication; mo = month or months; N or n = number of patients; normo = normobaric; n.s. = not (statistically) significant; OC = outcome; OR = odds ratio

2

An asterisk denotes a crossover trial.

From: Evidence Tables

Cover of Drug Treatments for the Prevention of Migraine Headache
Drug Treatments for the Prevention of Migraine Headache.
Technical Reviews, No. 2.3.
Gray RN, Goslin RE, McCrory DC, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.